This work was supported by an operating grant from Canadian Blood Services.
A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia (CME)
Article first published online: 9 APR 2012
© 2012 American Association of Blood Banks
Volume 52, Issue 11, pages 2466–2474, November 2012
How to Cite
Webert, K. E., Arnold, D. M., Lui, Y., Carruthers, J., Arnold, E. and Heddle, N. M. (2012), A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia (CME). Transfusion, 52: 2466–2474. doi: 10.1111/j.1537-2995.2012.03634.x
- Issue published online: 9 NOV 2012
- Article first published online: 9 APR 2012
- Received for publication November 11, 2011; revision received January 20, 2012, and accepted January 30, 2012.
BACKGROUND: Current scales to measure bleeding in clinical trials are inadequate. The aim of this study was to develop a simple, valid, and reliable measurement tool to categorize the severity of bleeding in patients with chemotherapy-induced thrombocytopenia (CIT).
STUDY DESIGN AND METHODS: Measurement theory was used to develop the Bleeding Severity Measurement Scale (BSMS) in four steps: 1) identification of the patient population, 2) item generation and reduction, 3) reviewing the items and formatting the scale, and 4) evaluation of psychometric properties. Feasibility was tested in a pilot study. Content and face validity were assessed by expert review. Psychometric evaluation included determination of intra- and interrater reliability and construct and criterion validity.
RESULTS: The final BSMS defined two grades of bleeding: not clinically significant (Grade 1) and clinically significant (Grade 2). Grade 2 bleeds were defined as bleeds resulting in morbidity, requiring interventions, or directly causing death. The BSMS had excellent interrater (intraclass correlation coefficient [ICC], 0.80) and intrarater (ICC, 1.0) reliability and good construct and criterion validity. The BSMS distinguished between patients with different bleeding severities.
CONCLUSION: Using rigorous methods, we designed a simple bleeding assessment tool with excellent psychometric properties for patients with CIT. Use of this scale in clinical trials should provide valid and reliable assessments of bleeding.